Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

2.150 -0.160 (-6.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ABVC BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q2 2024 ↗
ABVC BioPharma just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
News headline image
ABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024 ↗
ABVC BioPharma just reported results for the first quarter of 2024. 
Via InvestorPlace
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via NewMediaWire
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue
FREMONT, CA - (NewMediaWire) - June 12, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via NewMediaWire
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
FREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
News headline image
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
FREMONT, CA - (NewMediaWire) - May 09, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central... 
Via TheNewswire.com
News headline image
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
FREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
Topics Artificial Intelligence
News headline image
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence
News headline image
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
FREMONT, CA - (NewMediaWire) - April 10, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Why ABVC BioPharma Stock Is Up Today ↗
ABVC BioPharma said that the licensing agreement includes the ophthalmology pipeline, including the medical device Vitargus licensed products' and clinical trial, registration, manufacturing, supply,... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
FREMONT, CA - (NewMediaWire) - March 26, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
News headline image
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
FREMONT, CA - (NewMediaWire) - March 21, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology,... 
Via TheNewswire.com
News headline image
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.